about
Lifestyle-related factors in predementia and dementia syndromesUltrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the LiteratureHigh and low frequency transcutaneous electrical nerve stimulation inhibits nociceptive responses induced by CO2 laser stimulation in humans.Short-term effects of high-intensity laser therapy versus ultrasound therapy in the treatment of people with subacromial impingement syndrome: a randomized clinical trial.Short-term effects of high-intensity laser therapy versus ultrasound therapy in the treatment of low back pain: a randomized controlled trial.Immunopharmacology of the main herbal supplements: a review.Changes in actual and perceived physical abilities in clinically obese children: a 9-month multi-component intervention study.Vascular risk factors, alcohol intake, and cognitive decline.Dietary fatty acids, age-related cognitive decline, and mild cognitive impairment.Effectiveness of botulinum toxin type A treatment of neck pain related to nocturnal bruxism: a case report.Effect of intrathecal baclofen, botulinum toxin type A and a rehabilitation programme on locomotor function after spinal cord injury: a case report.Effectiveness of the frequency rhythmic electrical modulation system for the treatment of chronic and painful venous leg ulcers in older adults.Functional Gain After Inpatient Stroke Rehabilitation: Correlates and Impact on Long-Term Survival.Possible role of alpha-lipoic acid in the treatment of peripheral nerve injuries.Acoustic analysis of swallowing sounds: a new technique for assessing dysphagia.Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke.A multi-modal training programme to improve physical activity, physical fitness and perceived physical ability in obese children.SBOTE study: extracorporeal shock wave therapy versus electrical stimulation after botulinum toxin type a injection for post-stroke spasticity-a prospective randomized trial.Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study.Survival and functional outcome in patients 90 years of age or older after hip fracture.Assistive technology to help persons in a minimally conscious state develop responding and stimulation control: Performance assessment and social rating.Effect of botulinum toxin type A, motor imagery and motor observation on motor function of hemiparetic upper limb after stroke.Treatment of upper limb spasticity after stroke: one-year safety and efficacy of botulinum toxin type A NT201.Associated with intrathecal baclofen treatment and duloxetine in patients with multiple sclerosis.Psychopathological aspects and emotional behavior in right brain-damaged patients.Pulmonary rehabilitation for patients with bronchiectasis: case reports.Functional outcome and health status of injured patients with peripheral nerve lesions.Role of biphosphonates and lymphatic drainage type Leduc in the complex regional pain syndrome (shoulder-hand syndrome).Botulinum toxin type A and type B for sialorrhoea in Parkinson's disease: a case for switching therapy?Neuropsychiatric symptoms and the APOE genotype in Alzheimer's disease.Influence of nutritional status on cognitive, functional and neuropsychiatric deficits in Alzheimer's disease.Interleukin 6-174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease.Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques.Adhesive taping vs. daily manual muscle stretching and splinting after botulinum toxin type A injection for wrist and fingers spastic overactivity in stroke patients: a randomized controlled trial.Extracorporeal Shock Wave Therapy for the Treatment of Poststroke Plantar-Flexor Muscles Spasticity: A Prospective Open-Label StudyEffectiveness of Switching Therapy from Complexing Protein-containing Botulinum Toxin Type A to a Formulation with Low Immunogenicity in Spasticity after Stroke: A case reportEffect of botulinum toxin type A and modified constraint-induced movement therapy on motor function of upper limb in children with obstetrical brachial plexus palsyBotulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson’s diseaseBotulinum Toxin Type a in the Treatment of Painful Adductor Muscle Contracture After Total Hip ArthroplastyBotulinum Toxin Type A in the Treatment of Focal Hand Dystonia After Surgical Treatment for Thumb Duplication
P50
Q22241490-E3D81822-2EA5-4DB8-8027-E79190FFEE83Q26798457-3AA83CB7-3BB1-4C9F-8CCD-EDEE513512F4Q31141158-CA783BD6-6F03-4BF0-8378-341D8706892BQ33456607-90A87A7F-70BB-4327-837C-3F8BF799A022Q33926715-C899CABD-50E5-4C99-AE95-70CFFF2F6E43Q34399701-16FF7E84-A32C-46CC-8D07-24F326276C31Q34512226-924D1128-A0E9-40DA-926D-FDCB466A7EF2Q34786103-0E0C070A-E5CA-4330-88AA-9F304DDF5F1EQ37189375-7039668A-F50B-4C57-97E3-D3A52A529EB2Q38642797-1DA931AA-9A92-4DBA-92D9-F8279D6173A2Q39279226-1604D551-10E3-424C-BE20-8F48FA92A1B8Q40039827-FC9ADC90-FDBA-4AF5-BD78-A06B4B52FEB6Q41419458-F46673EE-4515-4CED-97B6-65ECA8D1B60AQ42426606-32FEE780-4901-4DF7-8C19-8B41A7D84F36Q44040233-7260A8B8-2FBB-4247-843D-DB6C205017C5Q44502462-17B3D13A-91FC-40DE-BD75-A69AC57675E3Q44655733-D959E618-A1C2-4F14-A1F7-0EDE9956F54FQ45852876-9D58769E-9C7C-4815-95F0-F46E0C027705Q46023892-F8E315A5-2777-40C5-AF9D-DF217596588AQ46758195-B3129CEA-B833-41ED-A7FF-DFAC06DE8D39Q47975515-87512628-4617-4DA4-A341-4D6EBE563DCFQ48157138-4D06CF92-E659-4B9D-AF9E-E693296B3A47Q48509514-0BCE72A9-409B-4379-9447-AF805001BCFDQ48772534-A2A070BB-0492-4F57-A154-570B7ED23E42Q48882778-0B223CA7-C0CC-4AAD-801F-49E9DFC54F10Q50950989-31E7484A-B6C3-4854-B2A9-EAADBD13C0FCQ51632214-637F106E-E914-4450-B4DB-C932BD287897Q51656104-65F7590D-20D5-4559-9719-335DAD0C868FQ51799841-A65275BA-9E92-4543-8628-4F604BA894C6Q51866283-23DF303E-4788-4AF8-AA77-4567330B2361Q53294008-C556EF9B-E103-4448-BBC7-D9C15C2651E8Q53305641-A128753C-D649-4C24-A7F6-453DA177FADFQ53431564-13A934E6-3A57-4E26-AF65-61A6B82B71CAQ53528429-FDC0F562-2BDE-473D-843B-564CDEB4B8CEQ58005657-180656C9-9CF9-4C0A-A301-A5AA91E04457Q58005687-95F3F9E7-31D5-47AF-8EE5-48C8C7C731D0Q58005740-DC199765-B8E7-43A6-818A-51731350E72DQ58005804-DBBFBDC0-5619-427D-AA24-4E7C5AEB7882Q58005855-E844E8B0-FA5D-4CC4-A4B1-4531E6129A14Q58005863-6DC37F01-2588-4EDB-851C-F3781F128BC0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pietro Fiore
@ast
Pietro Fiore
@en
Pietro Fiore
@es
Pietro Fiore
@nl
Pietro Fiore
@sl
Пьетро Фиоре
@ru
type
label
Pietro Fiore
@ast
Pietro Fiore
@en
Pietro Fiore
@es
Pietro Fiore
@nl
Pietro Fiore
@sl
Пьетро Фиоре
@ru
altLabel
PIETRO FIORE
@en
prefLabel
Pietro Fiore
@ast
Pietro Fiore
@en
Pietro Fiore
@es
Pietro Fiore
@nl
Pietro Fiore
@sl
Пьетро Фиоре
@ru
P106
P21
P31
P496
0000-0001-5621-2393